EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Dyne Therapeutics Inc (DYN) fair value: what the stock is really worth

As of Sep 22, 2026: fair value of Dyne Therapeutics Inc $4.69, price $17.14, upside -72.6%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US26818M1080

DT Dyne Therapeutics Inc logo Thin data Sep 24, 2026

Dyne Therapeutics Inc

DYN · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $4.69 · Strongly overvalued (−73%)
!Quality 31/100
!Weak Growth (revenue 5y +178.9 %/yr)
!negative free cash flow
!Trails peers (3/8)
!Narrow moat 12/100
✓Insider activity 66/100
!Evidence only low, so the estimate is less certain
Watch Dyne Therapeutics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$47.04 $4.36 Fair Value $4.69 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $4.36 – $47.04 · fair‑value band $3.09 – $5.86 · the $17.14 price screens above the $4.69 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Dyne Therapeutics in your weekly email

Every Wednesday you see whether Dyne Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

Show more

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Stock analysis

Dyne Therapeutics Inc (DYN) currently trades at $17.14, while our model-based Fair Value estimate is $4.69, implying the stock looks roughly 265.4% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $3.09 (bear) to $5.86 (bull), the price of $17.14 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Dyne Therapeutics Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$446M in FY2025.

Key figures

Market cap $4.0B · EPS (TTM) $−3.18 · Return on equity −58.9% · Return on assets (EBIT) −65.4% · Free cash flow −$405M · Net cash $873M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 113% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −73%, DYN screens richer than that median.

Fair Value models

Bear $3.09 Fair Value $4.69 Bull $5.86
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $2.94 $3.94 $5.88 51
All 1 models by family
Asset-Based
NCAV (Graham) $2.94 $3.94 $5.88 51

Open the full fair value analysis →

Notify me when DYN reaches fair value

Put DYN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 31/100

Of which business quality 36 · Market factors (momentum, volatility) 48

Profitability 0
Margins and returns on capital today
Quality Growth 75
Are margins and returns improving?
Cashflow 27
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 29
Calm price path (market factor)
Momentum 54
Price trend over the last 3–12 months (market factor)
52W Momentum 59
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 25/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−63.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−29.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+178.9%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−14.9% (2011) → −81.4% (2017)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

DYN screens 265% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Recent news

News mood ⓘNews mood, the average tone of recent news (86 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Negative
Recent news coverage is more negative than average.

Compare Dyne Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 648 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 36 · Below median
Fair Value upside −73% · Bottom 25%
Profitability
Return on assets −33% · Bottom 25%
Operating margin (TTM) 0% · Above median
Growth and dividend
Revenue growth 0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.08× · Priciest 25%
PEG 0.19× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BeOne Medicines AG ONC $368.08 $280.94 −24%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Dyne Therapeutics Inc · Fair Value
$4.69 −265%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Dyne Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/DYN

Frequently asked questions

Is Dyne Therapeutics Inc (DYN) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $4.69 versus a price of $17.14, about −73% upside (overvalued).
What is the fair value of DYN?
Our model-based fair value for Dyne Therapeutics Inc is $4.69 (as of Sep 24, 2026), built from audited fundamentals. The current price: $17.14.
What is the quality score of DYN?
Dyne Therapeutics Inc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dyne Therapeutics Inc (DYN)?
Our model-based price target is the fair value of $4.69 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $3.09, optimistic scenario $5.86. It is a calculation from audited fundamentals, not an analyst target.
What is the Dyne Therapeutics Inc stock forecast for 2026?
Our models put fair value at $4.69, about −73% upside versus a price of $17.14 (overvalued). Cautious scenario $3.09, optimistic scenario $5.86. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Dyne Therapeutics Inc (DYN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dyne Therapeutics Inc it is $4.69 per share (as of Sep 24, 2026), against a price of $17.14. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Dyne Therapeutics Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, DYN trades above its calculated fair value: price $17.14, fair value $4.69, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DYN?
No. The price is what the market pays today ($17.14); the fair value is what the company's own numbers justify ($4.69). For Dyne Therapeutics Inc the two are $12.45 per share apart. That gap is exactly why we show both numbers side by side.
How much is Dyne Therapeutics Inc worth?
The market values Dyne Therapeutics Inc at about $4.0B (market capitalisation, as of Sep 24, 2026). Per share that is $17.14; our models calculate a fair value of $4.69 per share.
What do the bullish and bearish scenarios say about DYN?
Our models span a range for Dyne Therapeutics Inc: cautious scenario $3.09, base $4.69, optimistic $5.86 per share (as of Sep 24, 2026, price $17.14). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of DYN?
The PEG ratio of Dyne Therapeutics Inc is 0.19 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Dyne Therapeutics Inc (DYN)?
Balance-sheet figures for Dyne Therapeutics Inc (as of Sep 24, 2026): return on equity −58.9%. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is DYN from its 52-week high?
Dyne Therapeutics Inc trades at $17.14, about 31% below its 52-week high of $25.00 and 113% above the low of $8.06 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $4.69 is for.
Which stocks are comparable to Dyne Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dyne Therapeutics Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $17.14, calculated fair value $4.69 (−73%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DYN calculated?
We run Dyne Therapeutics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.69, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Dyne Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dyne Therapeutics Inc (DYN)?
The closing price on Sep 22, 2026 was $17.14. Our model-based fair value is $4.69, about −73% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dyne Therapeutics Inc right now?
The price sits above even our optimistic bull case ($5.86). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($3.09 to $5.86) leaves room in how you read the outcome.

Key figures of Dyne Therapeutics Inc

How large is the market capitalisation of Dyne Therapeutics Inc (DYN)?
The market capitalisation of Dyne Therapeutics Inc is $4.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Dyne Therapeutics Inc (DYN)?
Earnings per share at Dyne Therapeutics Inc are $−3.18. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Dyne Therapeutics Inc (DYN)?
The return on equity (ROE) of Dyne Therapeutics Inc is −58.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dyne Therapeutics Inc (DYN)?
On an EBIT basis the return on assets of Dyne Therapeutics Inc is −65.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Dyne Therapeutics Inc (DYN) generate?
The free cash flow of Dyne Therapeutics Inc is −$405M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Dyne Therapeutics Inc (DYN) hold?
Dyne Therapeutics Inc holds more cash than debt, $873M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Dyne Therapeutics Inc in the live analysis

One click puts Dyne Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.